Aureka released Open Drug Discovery Engine (OpenDDE), an open-source, all-atom biomolecular foundation model aimed at AI-driven therapeutic discovery. The company says the model is designed to support structure modeling and co-folding as an entry point to downstream tasks, while positioning downstream capabilities—such as molecular design and clinical translation—as requiring additional validation. OpenDDE is offered under an Apache-2.0 license with Docker support, and it is presented as a “preview” rather than a turnkey discovery system. Aureka’s approach keeps the broader lab-linked workflow—experimental feedback loops and antibody discovery programs—inside the company, reflecting the tension in the AI biotech sector between public model artifacts and proprietary end-to-end performance. The move gives the market a tangible artifact in a space where investors and partners often must rely on proprietary claims about screening and discovery loops. It also signals continued momentum toward lab-linked systems, even as validation remains a central hurdle for the field.